13395-36-3

Usage

Uses

Used in Flavor and Fragrance Industry:
ETHYL TRIMETHYLACETOPYRUVATE is used as a flavor and fragrance ingredient for its sweet, fruity, and caramel-like odor, enhancing the sensory experience of various products.
Used in Pharmaceutical Synthesis:
ETHYL TRIMETHYLACETOPYRUVATE is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Production:
ETHYL TRIMETHYLACETOPYRUVATE is used as a component in the production of agrochemicals, aiding in the creation of agricultural products that improve crop yields and protect plants from pests.
Used in Organic Compound Synthesis:
ETHYL TRIMETHYLACETOPYRUVATE is used as a versatile building block in the synthesis of various organic compounds, facilitating the creation of a wide array of chemical products.
Used in Research and Development:
ETHYL TRIMETHYLACETOPYRUVATE is used in research and development for its potential pharmacological properties, including studies on its antioxidant and anti-inflammatory effects, which may lead to new therapeutic applications.

InChI:InChI=1/C10H16O4/c1-5-14-9(13)7(11)6-8(12)10(2,3)4/h6,11H,5H2,1-4H3/b7-6-

Upstream product

• 75-97-8 3,3-dimethyl-butan-2-one 
• 617-37-8 oxalic acid monoethyl ester 
• 95-92-1 oxalic acid diethyl ester 
• 7664-93-9 sulfuric acid 

Downstream Products

• 100616-09-9 6-tert-butyl-3-cyano-2-hydroxy-isonicotinic acid ethyl ester 
• 91252-54-9 5-tert-butylisoxazole-3-carboxylic acid ethyl ester 
• 75-97-8 3,3-dimethyl-butan-2-one 
• 17094-34-7 ethyl pivaloylacetate 
• 201230-82-2 carbon monoxide 
• 133261-10-6 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 194289-30-0 5-(1,1-dimethylethyl)-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 144-62-7 oxalic acid 
• 83405-70-3 ethyl 3-(tert-butyl)-1H-pyrazole-5-carboxylate 
• 160842-62-6 3-tert-Butyl-1-methyl-1H-pyrazole-5-carbonyl chloride 
• 175277-11-9 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylic acid 
• 194289-32-2 3-[(5-tert-Butyl-2-methyl-2H-pyrazole-3-carbonyl)-amino]-benzoic acid 

Relevant academic research and scientific papers

The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist

The development of selective CB2 receptor agonists is a promising therapeutic approach for the treatment of inflammatory diseases, without CB1 receptor mediated psychoactive side effects. Preliminary structure-activity relationship studies on pyrazoylidene benzamide agonists revealed the -ylidene benzamide moiety was crucial for functional activity at the CB2 receptor. A small library of compounds with varying linkage moieties between the pyrazole and substituted phenyl group has culminated in the discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist 19 (CB2R EC50 = 19 nM, CB1R EC50 > 10 μM). Docking studies have revealed key structural features of the linkage group that are important for potent functional activity.

The First Example of Azole-Fused Cyclic Anhydride Reacting in the Castagnoli-Cushman Way

Pyrazole-fused cyclic anhydrides have been employed for the first time as the Castagnoli-Cushman reaction partners to produce hitherto unknown 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5- a ]pyrazine-7-carboxylates in remarkably convenient and speedy fashion. At

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.

Design, synthesis and biological activity of novel substituted pyrazole amide derivatives targeting EcR/USP receptor

In order to discover highly active ecdysone analogs, a series of new substituted pyrazole amide derivatives were obtained using structure-guided optimization method and further screened for their insecticidal activities, in the basis of the core structures of the two active compounds N-(3-methoxyphenyl)-3-(tert-butyl)-1-phenyl-1H-pyrazole-5-carboxamide (6e) and N-(4-(tert-butyl)phenyl)-3-(tert-butyl)-1-phenyl-1H-pyrazole-5-carboxamide (6i), previously presented by us. The chemical structures of the title compounds were identified by spectral analyses. The preliminary bioassay results indicated that one among the synthesized pyrazole derivatives, compound 34, endowed with good activity against Mythimna Separata at 10 mg/L, which was equal to that displayed by the positive control tebufenozide. In addition, examples of molecular docking and molecular dynamics studies demonstrated that 34 may be the potential inhibitor to EcR and its docking conformation was similar to that of tebufenozide. In addition, increasing the hydrophobic effect and considering the suitable bulk effect on pyrazole ring are beneficial to the inhibiting activity to EcR and activity in vivo.

Target-based design, synthesis and biological activity of new pyrazole amide derivatives

Based on the similarities in the conformation of VS008 (N-(4-methylphenyl)-3-(tert-butyl)-1-(phenylmethyl)-1H-pyrazole-5-carboxamide) and BYIO6830 (N′-(3,5-dimethylbenzoyl)-N′-tert-butyl-5-methyl-2,3-dihydro-1,4-benzodioxine-6-carbohydrazide) bound to the active site of the EcR subunit of the ecdysone receptor (EcR)-ultraspiracle protein (USP) heterodimeric receptor, a series of new pyrazole amide derivatives were designed and synthesized. Their structures were confirmed by IR, 1HNMR, 13C NMR and elemental analysis. Results from a preliminary bioassay revealed that two of the pyrazole derivatives exhibited promising insecticidal activity. Specifically, compounds 6e and 6i exhibited good activity against Helicoverpa armigera (cotton bollworm) at low concentration. Symptoms displayed by tebufenozide-treated H. armigera were identical with those displayed by its treated counterpart. 6i showed the same poisoning symptoms as those of tebufenozide. In addition, results from molecular docking result indicated that the binding modes of 6e and 6i at the active site of the EcR subunit of the heterodimeric receptor were similar to that of the bound tebufenozide.

Synthesis of 3-(1,2-dioxoethyl)- and 2,3-dicarbonyl-containing pyrroles

The transition metal-catalyzed reaction of 2H-azirines with 1,2,4-tricarbonyl compounds leads to 3-(1,2-dioxoethyl)- and 2,3-dicarbonyl-pyrrole derivatives, useful building blocks for the preparation of 3-heterocyclyl pyrroles and pyrroles fused with heterocycles. The influence of catalysts and the reaction conditions on the yields of pyrroles and the regioselectivity of the reaction were studied. Experimental and theoretical results suggest that the reaction proceeds via the formation of an intermediate azirine-metal complex and subsequent nucleophilic N-C3 bond cleavage.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particular

PYRAZOLEPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particular

Novel compounds useful for the treatment of degenerative and inflammatory diseases

The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

Agonist lead identification for the high affinity niacin receptor GPR109a

A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.